ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 121 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.02 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,006,000 | -28.9% | 100,000 | 0.0% | 0.66% | -29.1% |
Q2 2023 | $2,821,000 | -23.6% | 100,000 | +25.0% | 0.93% | +16.2% |
Q1 2022 | $3,691,000 | -45.1% | 80,000 | 0.0% | 0.80% | -66.8% |
Q4 2021 | $6,725,000 | +55.2% | 80,000 | +23.1% | 2.41% | +90.2% |
Q3 2021 | $4,332,000 | – | 65,000 | – | 1.27% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |